Fennec Pharmaceuticals Stock Performance
| FENC Stock | USD 6.55 0.08 1.24% |
On a scale of 0 to 100, Fennec Pharmaceuticals holds a performance score of 12. The firm shows a Beta (market volatility) of 0.96, which means possible diversification benefits within a given portfolio. Fennec Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Fennec Pharmaceuticals is expected to follow. Please check Fennec Pharmaceuticals' downside variance, daily balance of power, and the relationship between the maximum drawdown and skewness , to make a quick decision on whether Fennec Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
12 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Fennec Pharmaceuticals are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating basic indicators, Fennec Pharmaceuticals exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.24 | Five Day Return 8.8 | Year To Date Return 4.13 | Ten Year Return 184.78 | All Time Return 111.97 |
Last Split Factor 1:3 | Last Split Date 2014-09-05 |
1 | Acquisition by Robert Andrade of 15816 shares of Fennec Pharmaceuticals at 2.45 subject to Rule 16b-3 | 11/18/2024 |
2 | Disposition of 400000 shares by Hackman Jeffrey S. of Fennec Pharmaceuticals at 5.58 subject to Rule 16b-3 | 11/25/2024 |
3 | Disposition of 6409 shares by Rallis Chris A of Fennec Pharmaceuticals at 6.14 subject to Rule 16b-3 | 12/02/2024 |
4 | Disposition of 1635 shares by Raykov Rosty of Fennec Pharmaceuticals at 6.13 subject to Rule 16b-3 | 12/03/2024 |
5 | Disposition of 7569 shares by Raykov Rosty of Fennec Pharmaceuticals at 6.08 subject to Rule 16b-3 | 01/06/2025 |
6 | Disposition of 4329 shares by Rallis Chris A of Fennec Pharmaceuticals at 2.31 subject to Rule 16b-3 | 01/15/2025 |
| Begin Period Cash Flow | 23.8 M |
Fennec |
Fennec Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 465.00 in Fennec Pharmaceuticals on November 2, 2024 and sell it today you would earn a total of 190.00 from holding Fennec Pharmaceuticals or generate 40.86% return on investment over 90 days. Fennec Pharmaceuticals is currently generating 0.6635% in daily expected returns and assumes 4.064% risk (volatility on return distribution) over the 90 days horizon. In different words, 36% of stocks are less volatile than Fennec, and 87% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Fennec Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Fennec Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Fennec Pharmaceuticals, and traders can use it to determine the average amount a Fennec Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1633
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | FENC | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.06 actual daily | 36 64% of assets are more volatile |
Expected Return
| 0.66 actual daily | 13 87% of assets have higher returns |
Risk-Adjusted Return
| 0.16 actual daily | 12 88% of assets perform better |
Based on monthly moving average Fennec Pharmaceuticals is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Fennec Pharmaceuticals by adding it to a well-diversified portfolio.
Fennec Pharmaceuticals Fundamentals Growth
Fennec Stock prices reflect investors' perceptions of the future prospects and financial health of Fennec Pharmaceuticals, and Fennec Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Fennec Stock performance.
| Return On Equity | -10.06 | ||||
| Return On Asset | 0.027 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | (0.75) % | ||||
| Current Valuation | 168.91 M | ||||
| Shares Outstanding | 27.43 M | ||||
| Price To Earning | (3.82) X | ||||
| Price To Book | 57.93 X | ||||
| Price To Sales | 3.60 X | ||||
| Revenue | 21.25 M | ||||
| Gross Profit | 46.15 M | ||||
| EBITDA | (12.36 M) | ||||
| Net Income | (16.05 M) | ||||
| Cash And Equivalents | 14.91 M | ||||
| Cash Per Share | 0.57 X | ||||
| Total Debt | 30.95 M | ||||
| Debt To Equity | 0.58 % | ||||
| Current Ratio | 5.12 X | ||||
| Book Value Per Share | (0.19) X | ||||
| Cash Flow From Operations | (17.14 M) | ||||
| Earnings Per Share | (0.04) X | ||||
| Market Capitalization | 177.49 M | ||||
| Total Asset | 26.86 M | ||||
| Retained Earnings | (219.25 M) | ||||
| Working Capital | 19.3 M | ||||
| Current Asset | 7.88 M | ||||
| Current Liabilities | 1.97 M | ||||
About Fennec Pharmaceuticals Performance
By analyzing Fennec Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Fennec Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Fennec Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Fennec Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 562.55 | 818.58 | |
| Return On Tangible Assets | (0.54) | (0.56) | |
| Return On Capital Employed | (0.60) | (0.57) | |
| Return On Assets | (0.54) | (0.56) | |
| Return On Equity | 1.24 | 1.30 |
Things to note about Fennec Pharmaceuticals performance evaluation
Checking the ongoing alerts about Fennec Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Fennec Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Fennec Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Fennec Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 21.25 M. Net Loss for the year was (16.05 M) with profit before overhead, payroll, taxes, and interest of 46.15 M. | |
| Fennec Pharmaceuticals currently holds about 14.91 M in cash with (17.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.57. | |
| Fennec Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 16.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Disposition of 400000 shares by Hackman Jeffrey S. of Fennec Pharmaceuticals at 5.58 subject to Rule 16b-3 |
- Analyzing Fennec Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Fennec Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Fennec Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Fennec Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Fennec Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Fennec Pharmaceuticals' stock. These opinions can provide insight into Fennec Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Fennec Stock analysis
When running Fennec Pharmaceuticals' price analysis, check to measure Fennec Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fennec Pharmaceuticals is operating at the current time. Most of Fennec Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Fennec Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fennec Pharmaceuticals' price. Additionally, you may evaluate how the addition of Fennec Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |